
Chinese cell therapy company formed as a joint venture within the PersonGen group, which develops chimeric antigen receptor T cell therapies and positions itself as a leader in CAR-T treatment of T cell malignancies. The group runs research and GMP manufacturing operations in Suzhou, Jiangsu and Hefei, Anhui, working on CD7, CD19 and other targeted CAR-T products together with universal cell therapy platforms.
Unternehmensprofil ansehen
Bewertung hinterlassen